Prostate cancer is one of the most common malignancies affecting the elderly male. Almost 1 in 10 males would be affected by it in their lifetime. It generally affects males after the age of 50 years but men with a family history of prostate cancer can be affected even at a much younger age. Recent research has shown that the number of men developing prostate cancer during their lifetime is going to increase. Diagnosing this cancer at its initial stages is of extreme importance, like in any other cancer, but more so in prostate cancer as it provides a window for complete cure from this cancer and normal life expectancy following radical therapy for early stages. Most of these cancers are asymptomatic to begin with in their earlier stages. However, the common presenting symptoms with which patients come to us are new onset difficulty in passing urine, poor urinary stream, frequent urination, blood in urine, urinary retention and back aches or bony pains, the latter seen in advanced and metastatic stages of the disease. A simple blood test called the Prostate Specific Antigen test can indicate whether the patient has prostate cancer or not and this can be confirmed with a histopathological examination, also known as the biopsy of the prostate. A MRI and a PSMA PET scan also helps in picking up this cancer and in staging the disease. Treatment depends on the stage of the disease. Early prostate cancer can be completely cured either by surgery or radiotherapy. However it is important to understand which is best for whom. Surgery involves  complete removal of the prostate and its surrounding structures along with the nearby lymph nodes. The surgery can be done robotically, laparoscopically or by open means. All 3 approaches have equal outcomes in terms of cancer free state. But the robotic and laparoscopic approaches involve a shorter hospital stay and less pain. Most of the patients would be completely treated with surgery alone and would not require any additional therapy apart from a regular follow up with Serum PSA levels. Patients with locally advanced disease may require additional hormone and radiation therapy after the surgical removal of the prostate depending upon the final histopathology report. Chemotherapy drugs are used to kill cancer cells or stop them from growing. While not typically the first-line treatment for prostate cancer, chemotherapy may be used when the cancer has spread beyond the prostate gland and is no longer responding to hormone therapy. Immunotherapy works by stimulating the body’s immune system to recognize and attack cancer cells. Drugs known as checkpoint inhibitors, such as pembrolizumab and ipilimumab, have shown promise in treating advanced prostate cancer in some patients. Targeted therapy drugs are designed to specifically target molecules or pathways involved in cancer growth and spread. For example, drugs that target the androgen receptor pathway, such as enzalutamide and abiraterone, are used to treat advanced prostate cancer that has become resistant to hormone therapy. Alongside cancer-directed treatments, supportive care plays a crucial role in managing prostate cancer. This includes managing symptoms such as pain, providing psychological support, and addressing side effects of treatment to improve the patient’s quality of life. Participation in clinical trials may offer access to innovative treatments and contribute to advancements in prostate cancer management. These trials test new drugs, treatment combinations, or techniques to improve outcomes for patients with prostate cancer. The management of prostate cancer is evolving rapidly with ongoing research and advancements in treatment modalities. A personalized approach that considers the unique characteristics of each patient’s cancer is essential for achieving the best possible outcomes. Regular follow-up and monitoring are also important to detect any signs of recurrence or progression early and adjust treatment as needed.